Metformin Use in Patients with eGFR 36

Introduction to Metformin Guidelines

• The American Diabetes Association recommends using eGFR thresholds rather than serum creatinine alone for metformin prescribing decisions, with standard dosing for eGFR ≥45 mL/min/1.73 m² 1, 2
• For patients with eGFR 30-44 mL/min/1.73 m², metformin can be used but requires dose reduction to a maximum of 1,000 mg/day, as recommended by the American Diabetes Association 1, 2

Dosing and Monitoring Recommendations

• The American Diabetes Association suggests starting with 500 mg daily and titrating slowly, not exceeding 1,000 mg total daily dose, and dividing doses to minimize gastrointestinal side effects 1, 3
• Monitoring eGFR every 3-6 months once metformin is restarted is critical, as patients with eGFR in the 30-44 range are at higher risk for further renal function decline, according to the American Diabetes Association 1, 3

Contraindications and Precautions

• Metformin must be temporarily discontinued in specific situations, including acute illness, contrast procedures, acute kidney injury, and hospitalization, as recommended by The Lancet Diabetes and Endocrinology 4, 3

Risk-Benefit Considerations

• The evidence strongly favors restarting metformin at eGFR 36 when appropriately dosed, with benefits including reduced risk of major adverse cardiovascular events and lower all-cause mortality, according to the American Diabetes Association 2
• The actual risk of metformin-associated lactic acidosis remains very low even in eGFR 30-45 range when properly dosed, as reported by the American Diabetes Association 1

Alternative Treatment Options

• If there are concerns about restarting metformin, consider alternative treatments such as DPP-4 inhibitors, GLP-1 receptor agonists, or SGLT2 inhibitors, as recommended by the American Diabetes Association 5, 3, 4